AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial
Top Cited Papers
Open Access
- 8 July 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (9) , 2623-2630
Abstract
Screening mammography reduces breast cancer mortality, but studies analyzing interval cancers diagnosed after negative screens have shown that many cancers are missed. Supplemental screening using magnetic resonance imaging (MRI) can reduce the number of missed cancers. However, as qualified MRI staff are lacking, the equipment is expensive to purchase and cost-effectiveness for screening may not be convincing, the utilization of MRI is currently limited. An effective method for triaging individuals to supplemental MRI screening is therefore needed. We conducted a randomized clinical trial, ScreenTrustMRI, using a recently developed artificial intelligence (AI) tool to score each mammogram. We offered trial participation to individuals with a negative screening mammogram and a high AI score (top 6.9%). Upon agreeing to participate, individuals were assigned randomly to one of two groups: those receiving supplemental MRI and those not receiving MRI. The primary endpoint of ScreenTrustMRI is advanced breast cancer defined as either interval cancer, invasive component larger than 15 mm or lymph node positive cancer, based on a 27-month follow-up time from the initial screening. Secondary endpoints, prespecified in the study protocol to be reported before the primary outcome, include cancer detected by supplemental MRI, which is the focus of the current paper. Compared with traditional breast density measures used in a previous clinical trial, the current AI method was nearly four times more efficient in terms of cancers detected per 1,000 MRI examinations (64 versus 16.5). Most additional cancers detected were invasive and several were multifocal, suggesting that their detection was timely. Altogether, our results show that using an AI-based score to select a small proportion (6.9%) of individuals for supplemental MRI after negative mammography detects many missed cancers, making the cost per cancer detected comparable with screening mammography. ClinicalTrials.gov registration: NCT04832594.Keywords
This publication has 32 references indexed in Scilit:
- Factors promoting breast, cervical and colorectal cancer screenings participation: A systematic reviewPsycho-Oncology, 2022
- Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI)European Radiology, 2022
- The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control studyThe Breast, 2021
- A Multi-million Mammography Image Dataset and Population-Based Screening Cohort for the Training and Evaluation of Deep Neural Networks—the Cohort of Screen-Aged Women (CSAW)Journal of Digital Imaging, 2019
- Contrast‐enhanced MRI for breast cancer screeningJournal of Magnetic Resonance Imaging, 2019
- The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screeningnpj Breast Cancer, 2017
- Application of Abbreviated Protocol of Magnetic Resonance Imaging for Breast Cancer Screening in Dense Breast TissueAcademic Radiology, 2017
- Magnetic resonance imaging: The evolution of breast imagingThe Breast, 2013
- The benefits and harms of breast cancer screening: an independent reviewBritish Journal of Cancer, 2013
- Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic PredispositionNew England Journal of Medicine, 2004